The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer

Mitsuru Miyazaki, Yasuhiro Fujiwara, Takeshi Isobe, Michio Yamakido, Takashi Kato, Hiroshi Miyazaki

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To clarify the relationship between the carboplatin AUC and the extent of damage to thrombopoiesis, we monitored both endogenous serum TPO kinetics and carboplatin pharmacokinetics after single-agent carboplatin administration. Previously untreated 12 patients with stage IV non-small-cell lung cancer were enrolled. The actual carboplatin AUC showed a significant positive correlation with the maximum increase ratio of TPO (TPO(max)/TPO(day1) (r = 0.74, p = 0.014). Furthermore, the increase ratio of TPO at one week after administration of carboplatin (TPO(day8)/TPO(day1) showed a significant negative correlation with the following platelet nadir around day 19 (r = -0.84, p = 0.005). By monitoring the changes in endogenous TPO concentration, we could estimate the degree of thrombocytopenia and determine the indication, and thus the optimal timing of prophylactic administration of TPO before platelets are markedly reduced.

Original languageEnglish
Pages (from-to)667-670
Number of pages4
JournalAnticancer Research
Volume19
Issue number1 B
Publication statusPublished - 1999 Apr 20
Externally publishedYes

Keywords

  • Carboplatin
  • Lung cancer
  • Pharmacokinetics
  • Thrombocytopenia
  • Thrombproietin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Miyazaki, M., Fujiwara, Y., Isobe, T., Yamakido, M., Kato, T., & Miyazaki, H. (1999). The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer. Anticancer Research, 19(1 B), 667-670.